Trials / Enrolling By Invitation
Enrolling By InvitationNCT05593588
Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Avni Joshi · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fisetin | 20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29 |
| DRUG | Placebo | Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29 |
Timeline
- Start date
- 2023-04-12
- Primary completion
- 2026-05-01
- Completion
- 2026-12-01
- First posted
- 2022-10-25
- Last updated
- 2026-01-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05593588. Inclusion in this directory is not an endorsement.